BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16398403)

  • 21. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer.
    Petrović M; Baskić D; Banković D; Ilić N
    Biomarkers; 2011 Jun; 16(4):311-20. PubMed ID: 21595568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Multidrug resistance and its relationship with neuroendocrine differentiation in non-small cell lung carcinoma].
    Yu SP; Xiong YY; Tian SF
    Zhonghua Jie He He Hu Xi Za Zhi; 2003 Mar; 26(3):165-8. PubMed ID: 12816683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
    Carles J; Rosell R; Ariza A; Pellicer I; Sanchez JJ; Fernandez-Vasalo G; Abad A; Barnadas A
    Lung Cancer; 1993 Dec; 10(3-4):209-19. PubMed ID: 7521264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase.
    Giovanella L; Ceriani L; Bandera M; Garancini S
    Int J Biol Markers; 2001; 16(1):50-5. PubMed ID: 11288956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
    Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
    Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic value of four neuroendocrine markers in small cell neuroendocrine carcinomas of the cervix: a meta-analysis.
    Huang R; Yu L; Zheng C; Liang Q; Suye S; Yang X; Yin H; Ren Z; Shi L; Zhang Z; Chen H; Fu C
    Sci Rep; 2020 Sep; 10(1):14975. PubMed ID: 32917946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [On detection of chromogranin A, synaptophysin, neuronspecific enolase and progastrin-releasing peptide in small cell lung cancer].
    Lu QQ; Li J; Li YH; Liu H; Xie XB
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jul; 56(7):1017-1022. PubMed ID: 35899358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
    Zhou HH; Liu LY; Yu GH; Qu GM; Gong PY; Yu X; Yang P
    Anticancer Res; 2017 Aug; 37(8):4529-4537. PubMed ID: 28739749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.
    Pujol JL; Boher JM; Grenier J; Quantin X
    Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
    Kasprzak A; Zabel M; Biczysko W
    Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secretagogin is a new neuroendocrine marker in the human prostate.
    Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
    Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and Clinicopathological Significance of SOX11 in Small-Cell Lung Cancer.
    Xinli W; Lixiao W; Baoqi D; Hu H; Qiang Z
    Biomed Res Int; 2022; 2022():1707914. PubMed ID: 35402616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study.
    Kiriakogiani-Psaropoulou P; Malamou-Mitsi V; Martinopoulou U; Legaki S; Tamvakis N; Vrettou E; Fountzilas G; Skarlos D; Kosmidis P; Pavlidis N
    Lung Cancer; 1994 Dec; 11(5-6):353-64. PubMed ID: 7535640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.
    Georgantzi K; Sköldenberg EG; Stridsberg M; Kogner P; Jakobson Å; Janson ET; Christofferson RHB
    Pediatr Hematol Oncol; 2018 Mar; 35(2):156-165. PubMed ID: 29737901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cut-off levels of NSE to differentiate SCLC from NSCLC.
    Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
    Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neuroendocrine differentiation as a survival prognostic factor in advanced non-small cell lung cancer].
    Petrović M; Tomić I; Ilić S
    Vojnosanit Pregl; 2007 Aug; 64(8):525-9. PubMed ID: 17874719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression.
    Wertzel H; Grahmann PR; Bansbach S; Lange W; Hasse J; Böhm N
    Eur J Cardiothorac Surg; 1997 Nov; 12(5):698-702. PubMed ID: 9458138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas.
    Linnoila RI; Mulshine JL; Steinberg SM; Funa K; Matthews MJ; Cotelingam JD; Gazdar AF
    Am J Clin Pathol; 1988 Dec; 90(6):641-52. PubMed ID: 2848408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
    Lamy PJ; Grenier J; Kramar A; Pujol JL
    Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary large cell carcinoma expressing neuroendocrine markers: the morphological, biological, and neuroendocrine features of their cell lines and surgical cases.
    Kasai K; Kameya T; Kawakubo Y; Sato Y; Wada C; Itoh H
    Jpn J Cancer Res; 1992 Sep; 83(9):1002-10. PubMed ID: 1331003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.